3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
32
Cisplatin
23
Cetuximab
14
Carboplatin
13
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Nivolumab
9
Docetaxel
8
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Radiotherapy
5
Biopsy
5
dostarlimab
4
atezolizumab
4
Immunoglobulin G
4
Disulfides
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Taxes
3
Radiation
3
Fulvestrant
3
Fluorouracil
3
budigalimab
2
amivantamab
2
abemaciclib
2
Radiotherapy, Image-Guided
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled